On the latest episode of The Bioverge Podcast, Amit Etkin, Founder and CEO of Alto Neuroscience, sits down with Neil Littman to discuss the lack of innovation in psychiatric medicines, how Alto has identified AI-derived brain biomarkers, and how that is fueling its pipeline of precision therapies to treat mental health disorders.

Vineeta Agarwala, General Partner at Andreessen Horowitz and lead of the firm’s bio and health fund, sits down with Neil to discuss her investment process, how technology is transforming biotech and healthcare, and why she thinks drug development becoming more and more like software development.

David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.

Neil is the Founder & CEO of Bioverge Ventures, an investment platform democratizing access to enable individuals to diversify their portfolio with private biotech and healthcare investments for the purposes of long-term wealth creation.

JelikaLite has developed the first home-based, non-invasive stimulation device for children with autism. Known as Cognilum, it combines a wearable neurostimulation and EEG-sensing device with an AI-driven data platform in an integrated system to analyze developmental trajectory and personalize future treatments in a feedback loop.

Peter Kolchinsky, Founder and Managing Director of RA Capital Management and Founder of the nonprofit No Patient Left Behind, sits down with Neil to discuss his book “The Great American Drug Deal,” policy fights over pricing, and his organization’s efforts to make medicines affordable for all Americans.

Kriya Therapeutics Co-Founder, Chairman, and CEO Shankar Ramaswamy sits down with Neil to discuss how the company is changing the way gene therapies are designed, developed, and manufactured in an effort to cut costs, accelerate the time to market, and expand the reach of gene therapy to a broad universe of disease.

Francisco Gimenez, Partner at 8VC, sits down with Neil to discuss how his background in data science and bioinformatics shapes his investment approach and the potential to transform drug development with technology.

D.A. Wallach sits down with Neil to discuss his journey from recording artists to venture investors, his co-founding of Time BioVentures, and his vision from transforming biotechnology and healthcare with technology.